Screening for diabetic retinopathy in diabetic outpatient clinics using arteficial intelligence: a pilot project of the Slovak Diabetes Society
Authors:
Viera Doničová
Authors‘ workplace:
Interná a diabetologická ambulancia, Košice
Published in:
Diab Obez 2023; 23(46): 87-90
Category:
Reviews
Overview
The development of technology brings new possibilities for diagnosis and screening of diabetic complications. One of them is the possibility of using a non-mydriatic fundus camera, where the acquired scans of the ocular background are evaluated using artefactual intelligence to assess the presence and degree of diabetic retinopathy. The Slovak Diabetes Society conducted a pilot project in diabetic outpatient clinics and mapped the prevalence of diabetic retinopathy across Slovakia. The project involved 32 diabetes clinics. The overall DR prevalence was 31% in central and eastern Slovakia and 22.5% in western Slovakia.
Keywords:
type 1 diabetes (T1D) – arteficial inteligency (AI) – diabetic retinopathy (DR) – fundus camera – screening of diabetic retinopathy – type 2 diabetes (T2D)
Sources
- Rajesh AE, Davidson AY, Lee CS. Artificial Intelligence and Diabetic Retinopathy: AI Framework, Prospective Studies, Head-to-head Validation, and Cost-effectiveness. Diabetes Care 2023; 46(10): 1728–1739. Dostupné z DOI: <https://doi.org/10.2337/dci23–0032>.
- Vujosevic S, Aldington SJ, Silva P et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol 2020; 8(4): 337–347. Dostupné z DOI: <https://doi/10.1016/S2213–8587(19)30411–5>.
- Abramoff MD, Cunningham B, Patel B et al. Collaborative Community on Ophthalmic Imaging Executive Committee and Foundational Principles of Ophthalmic Imaging and Algorithmic Interpretation Working Group. Foundational considerations for artificial intelligence using ophthalmic images. Ophthalmology 2022; 129(2): e14-e32. Dostupné z DOI: <https://doi: 10.1016/j.ophtha.2021.08.023>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2023 Issue 46
Most read in this issue
- Prevalence and mortality of patients with type 2 diabetes mellitus in 2010–2015 and mortality during the COVID pandemic (April 2020–March 2021)
- Prevalence of obesity and type 2 diabetes mellitus
- Cardio-renal and metabolic benefits of empagliflozin: additional indication and change in indication restrictions
- Screening for diabetic retinopathy in diabetic outpatient clinics using arteficial intelligence: a pilot project of the Slovak Diabetes Society